Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
Abstract Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-022-01250-2 |
| _version_ | 1818571742303485952 |
|---|---|
| author | Mathieu Leclerc Rabah Redjoul Anne Le Bouter Florence Beckerich Christine Robin Vincent Parinet Cécile Pautas Dehbia Menouche Selwa Bouledroua Lydia Roy Ludovic Cabanne Yakout Nait-Sidenas Slim Fourati Sébastien Maury |
| author_facet | Mathieu Leclerc Rabah Redjoul Anne Le Bouter Florence Beckerich Christine Robin Vincent Parinet Cécile Pautas Dehbia Menouche Selwa Bouledroua Lydia Roy Ludovic Cabanne Yakout Nait-Sidenas Slim Fourati Sébastien Maury |
| author_sort | Mathieu Leclerc |
| collection | DOAJ |
| description | Abstract Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died. |
| first_indexed | 2024-12-14T18:48:22Z |
| format | Article |
| id | doaj.art-82f8e840ef4b465e80477f5981d54ca5 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-14T18:48:22Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-82f8e840ef4b465e80477f5981d54ca52022-12-21T22:51:20ZengBMCJournal of Hematology & Oncology1756-87222022-03-011511610.1186/s13045-022-01250-2Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipientsMathieu Leclerc0Rabah Redjoul1Anne Le Bouter2Florence Beckerich3Christine Robin4Vincent Parinet5Cécile Pautas6Dehbia Menouche7Selwa Bouledroua8Lydia Roy9Ludovic Cabanne10Yakout Nait-Sidenas11Slim Fourati12Sébastien Maury13Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Virology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Hematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)INSERM U955, Paris Est Créteil University UPECHematology Department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErsHenri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)Abstract Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died.https://doi.org/10.1186/s13045-022-01250-2SARS-CoV-2Hematopoietic stem cell transplantationImmune responsemRNA vaccineCOVID-19 |
| spellingShingle | Mathieu Leclerc Rabah Redjoul Anne Le Bouter Florence Beckerich Christine Robin Vincent Parinet Cécile Pautas Dehbia Menouche Selwa Bouledroua Lydia Roy Ludovic Cabanne Yakout Nait-Sidenas Slim Fourati Sébastien Maury Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients Journal of Hematology & Oncology SARS-CoV-2 Hematopoietic stem cell transplantation Immune response mRNA vaccine COVID-19 |
| title | Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| title_full | Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| title_fullStr | Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| title_full_unstemmed | Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| title_short | Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| title_sort | determinants of sars cov 2 waning immunity in allogeneic hematopoietic stem cell transplant recipients |
| topic | SARS-CoV-2 Hematopoietic stem cell transplantation Immune response mRNA vaccine COVID-19 |
| url | https://doi.org/10.1186/s13045-022-01250-2 |
| work_keys_str_mv | AT mathieuleclerc determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT rabahredjoul determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT annelebouter determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT florencebeckerich determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT christinerobin determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT vincentparinet determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT cecilepautas determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT dehbiamenouche determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT selwabouledroua determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT lydiaroy determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT ludoviccabanne determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT yakoutnaitsidenas determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT slimfourati determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients AT sebastienmaury determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients |